• Xolatryp significantly protected cardiac function against doxorubicin-induced cardiotoxicity
• Functional protection comparable to dexrazoxane, evident at Week 3 and sustained through Week 5
• Histopathology showed reduced myocardial injury with Xolatryp
• Xolatryp has anti-tumour activity and enhances doxorubicin's anti-tumour effects
• Nyrada plans to assess a potential Phase Ib clinical trial for Xolatryp

Nyrada Inc. reported that Xolatryp significantly protected cardiac function against progressive doxorubicin-induced cardiotoxicity in a preclinical study, with benefits across four key measures of heart performance. The magnitude of functional protection was comparable to dexrazoxane, the only approved cardioprotective agent, and was evident at Week 3 and sustained through Week 5. Histopathology analysis supported these functional findings, with myocardial injury reduced from predominantly moderate focal injury with doxorubicin alone to predominantly mild focal injury with Xolatryp. Combined with previously reported tumour-model data showing anti-tumour activity with Xolatryp alone and additive activity with doxorubicin, the findings support Xolatryp's potential as a differentiated adjunct to anthracycline therapy, addressing a significant unmet clinical need.

Nyrada plans to assess the design and feasibility of a potential Phase Ib clinical trial of Xolatryp in the oncology setting.